Paragon 28

Paragon 28, Inc. engages in operation of an orthopedic foot and ankle company. Its products include bone graft harvest system, bone marrow aspirate kits, and soft tissue fixation system. The company was founded by Albert DaCosta, Frank Bono, Jim Riegler and Lee Rosenthal in 2010 and is headquartered in Englewood, CO.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Paragon 28 reports strong revenue growth and strategic initiatives outlook

Paragon 28 delivered robust financial results in Q4 2022 and full-year 2022, driven by strong revenue growth in the U.S. and international markets.
While facing challenges in achieving profitability and commercializing new technologies, the company's focus on innovation and market expansion presents opportunities for future growth.
With a solid liquidity position and strategic initiatives in place, Paragon 28 is well-positioned to capitalize on market opportunities and drive continued performance.
Investors can look forward to the company's projected revenue growth in 2023 and advancements in technology adoption for improved patient outcomes.

Paragon 28 reports record Q1 revenue, eyes global growth opportunities

Paragon 28 delivered robust financial performance in Q1 2023, driven by strong revenue growth in the U.S. and internationally. While challenges in achieving profitability persist, the company's strategic focus on product development and global market expansion positions it for continued success. Opportunities for growth include optimizing sales force efficiency, launching new products, and capitalizing on international market strength.

Paragon 28 reports strong Q2 performance, eyes international expansion

Paragon 28's Q2 2023 earnings call reflects robust financial performance, driven by international growth and successful product launches.
While facing supply chain challenges and anticipating a growth slowdown, the company remains focused on expanding its market reach and product offerings.
Investments in key markets and a strategic focus on emerging growth drivers underscore Paragon 28's commitment to sustained revenue growth.
Prudence in guidance and operational planning amidst uncertainties highlights the company's proactive approach to managing challenges and seizing opportunities.

Paragon 28 reports steady Q3 growth amidst supply chain challenges

Paragon 28's Q3 2023 earnings call highlighted steady revenue growth, product innovation, and strategic investments driving performance.
While facing supply chain challenges and billing day impacts, the company's focus on market-specific strategies and surgeon training remains a strength.
Securing a new credit facility and reaffirming revenue guidance underscore Paragon 28's commitment to future growth and market leadership.

Paragon 28 reports robust Q4 performance, eyes growth in 2024

Paragon 28's strong performance in Q4 2023, coupled with expectations for growth in 2024, positions the company well for the future. Despite challenges like supply chain issues, the company's focus on innovation and market expansion presents significant opportunities. By maintaining accountability and leveraging market opportunities, Paragon 28 aims to drive continued success.

Paragon 28 reports record Q1 revenue, eyes growth opportunities

Paragon 28's Q1 2024 performance reflects strong revenue growth and strategic product launches.
While facing challenges like negative cash flow and increased SG&A expenses, the company remains optimistic.
Opportunities lie in upcoming product launches, market expansion, and engagement with investors.
Overall, Paragon 28's resilience and growth trajectory position it well for future success in the medical devices sector.

Paragon 28 reports record revenue and positive EBITDA in Q3

Paragon 28's Q3 2024 performance reflects strong revenue growth, product innovation, and a milestone in positive adjusted EBITDA post-IPO.
The company's emphasis on operational efficiency and cost optimization positions it well for sustained profitability and growth.
While facing challenges in cash flow and margin stabilization, Paragon 28 has opportunities to capitalize on its strengths and drive further expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Paragon 28, Inc. (NYSE:FNA ) Q4 2022 Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Matt Brinckman - Investor Relations Albert DaCosta - Chairman and Chief Executive Officer Stephen Deitsch - Chief Financial Officer Conference Call Participants Kyle Rose - Canaccord Craig Bijou - Bank of America Mike Matson - Needham David Turkaly - JMP Securities Neil Chatterji - B. Riley Operator Good afternoon, and welcome to the Paragon 28's Fourth Quarter 2022 Earnings Conference Call.

Paragon 28, Inc. (FNA) Q4 2022 Earnings Call Transcript

Paragon 28, Inc. (FNA) delivered earnings and revenue surprises of -466.67% and 2.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Paragon 28, Inc. (FNA) Reports Q4 Loss, Tops Revenue Estimates

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter and year ended December 31, 2022. Fourth Quarter and Full Year 2022 Financial Results Consolidated net revenue for the fourth quarter of 2022 was $51.5 million, representing 20.4% and 22.1% reported and constant currency growth, respectively.

Paragon 28 Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance

Paragon 28, Inc. (FNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Paragon 28, Inc. (FNA) Q4 Earnings Expected to Decline

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc.

Paragon 28, Inc. Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the fourth quarter and full year 2022 after market close on Thursday, March 2, 2023. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time.

Paragon 28 To Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023

AAR CORP.

Insteel Industries

Kura Oncology

PureCycle Technologies

Seabridge Gold

SMART Global Hlds

Stocks are showing signs of life in 2023. And if you have a tolerance for risk and are willing to look for stocks to trade, the small-cap sector is one area to find stocks to watch.

7 Undiscovered Stocks to Watch for the Next Big Thing

ENGLEWOOD, Colo.--( BUSINESS WIRE )--Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the pricing of the previously announced underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $17.00 per share, before underwriting discounts and commissions. 3,750,000 shares in the offering are being offered for sale by Paragon and 2,750,000 shares are being offered for sale by certain selling securityholders. In addition, Paragon and the selling securityholders have granted the underwriters a 30-day option to purchase up to an additional 562,500 and 412,500 shares of Paragon's common stock, respectively, at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Paragon are expected to be approximately $63.8 million. Paragon will not receive any proceeds from the sale of common stock by the selling securityholders. The offering is expected to close on January 30, 2023, subject to customary closing conditions.

Paragon 28, Inc. Announces Pricing of Public Offering

ENGLEWOOD, Colo.--( BUSINESS WIRE )--Paragon 28, Inc. (NYSE: FNA) (“Paragon”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today the commencement of a proposed underwritten public offering of 6,500,000 shares of its common stock, consisting of 3,750,000 shares offered by Paragon and 2,750,000 shares offered by certain selling securityholders. Paragon and the selling securityholders also expect to grant the underwriters a 30-day option to purchase up to an additional 562,500 and 412,500 shares of common stock, respectively. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Paragon 28, Inc. Announces Proposed Public Offering of Common Stock

ENGLEWOOD, Colo.--( BUSINESS WIRE )--Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “P28”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced a range of its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2022.

Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022

ENGLEWOOD, Colo.--( BUSINESS WIRE )--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Thursday, December 1, 2022 at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.

Paragon 28 to Present at The 34th Annual Piper Sandler Healthcare Conference

The consensus price target hints at a 33.5% upside potential for Paragon 28, Inc. (FNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Paragon 28, Inc. (FNA) Could Surge 34%: Read This Before Placing a Bet

Paragon 28, Inc. (NYSE:FNA ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Brinckman - IR Albert DaCosta - Co Founder, President and Chief Executive Officer Stephen Deitsch - Chief Financial Officer Conference Call Participants Kyle Rose - Canaccord Mike Matson - Needham & Company Craig Bijou - Bank of America Dave Turkaly - JMP Securities Operator Good afternoon, and welcome to Paragon 28 Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Paragon 28, Inc. (FNA) Q3 2022 Earnings Call Transcript

ENGLEWOOD, Colo.--( BUSINESS WIRE )--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended September 30, 2022 and increased its 2022 net revenue guidance.

Paragon 28 Reports Third Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance

Paragon 28 To Report Third Quarter 2022 Financial Results on November 10, 2022

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will be presenting at the Morgan Stanley 20th Annual Global Healthcare Conference. Mr. DaCosta and Mr. Deitsch will be hosting a fireside chat presentation on Tuesday, September 13th, 2022, at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time. A live webcast, as

Paragon 28 to Present at The Morgan Stanley 20th Annual Global Healthcare Conference

Paragon 28, Inc. (NYSE:FNA ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Matt Bacso - Gilmartin Group Albert DaCosta - Co Founder, President and Chief Executive Officer Stephen Deitsch - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Kyle Rose - Canaccord Mike Mattson - Needham David Turkaly - JMP Securities Operator Good afternoon and welcome to the Paragon 28's Second Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

Paragon 28, Inc. (FNA) CEO Albert DaCosta on Q2 2022 Results - Earnings Call Transcript

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced two changes to the composition of its Board of Directors. Quentin Blackford has joined the Company's Board of Directors and will serve the Company as Chairman of its Compensation Committee and as a member of its Audit Committee. Mr. Blackford has more than two decades of senior leadership experience with global medical dev

Paragon 28 Announces Changes to its Board of Directors

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today reported financial results for the quarter ended June 30, 2022 and increased its 2022 revenue guidance. Financial Highlights Net revenue $42.5 million for the second quarter of 2022, representing growth of 19% over the second quarter of 2021. Strengthening of the U.S. dollar reduced second quarter 2022 net revenue growth

Paragon 28 Reports Second Quarter 2022 Financial Results and Increases 2022 Net Revenue Guidance

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2022 after market close on Wednesday, August 3, 2022. The company's management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing (844-200-6205) for dome

Paragon 28 To Report Second Quarter 2022 Financial Results on August 3, 2022

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will be presenting at The Canaccord Genuity 42nd Annual Growth Conference in Boston. The Canaccord Genuity fireside chat will be webcast live on August 11, 2022, at 1:00pm Eastern Time. A live webcast, as well as the archived recording, will be available on the i

Paragon 28 to Present at The Canaccord Genuity 42nd Annual Growth Conference

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced its new nationwide mobile training lab tour, for convenient, on-site surgeon training and education. Paragon 28's new mobile lab is housed in a 43x30 foot tractor-trailer which includes a state-of-the-art, 6-station, cadaveric training facility accommodating up to 20 surgeons. The mobile lab will host over 50 training sess

Paragon 28 Launches Mobile Medical Education Lab Tour, Expanding Opportunities for Foot and Ankle Surgeon Education

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the launch of its Monkey Rings™ Circular External Fixation System for trauma, deformity correction, and limb salvage. The Monkey Rings Circular External Fixation System is designed to use external wires and screws that can be fixed into bone to maintain anatomic position while providing stability, preservation of soft tiss

Paragon 28 Launches Monkey Rings™ Circular External Fixation System

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced further expansion of its hammertoe and soft-tissue portfolio with the launch of its TenoTac™ 2.0 Soft Tissue Fixation System. The TenoTac™ 2.0 Soft Tissue Fixation System uses a titanium threaded implant and was designed to allow for greater capture of soft tissue, streamlined tensioning, and improved fit to the bony surfa

Paragon 28 Launches TenoTac™ 2.0 Soft Tissue Stabilization System for Hammertoe and Soft Tissue Repair

ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced today an expansion of its soft-tissue portfolio with the launch of its Grappler™ Suture Anchor System. The Grappler™ Suture Anchor System provides surgeons an alternative fixation option designed to limit implant migration and loss of tension for intraoperative tissue reattachment and fixation in the foot and ankle. “We are exci

News for Paragon 28 Stock (FNA)